Skip to contentM
Medifast Inc
M
MEDMedifast Inc Q2 2024 · 10-Q
Revenue$168.56M$168.56M−43.1% vs Q2 2023 Net Income-$8.15M-$8.15MN/M vs Q2 2023 EPS Diluted-$0.75-$0.75N/M vs Q2 2023 Gross Profit$123,438,000−41.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Medifast Inc · CIK 910329 · Engraved from SEC EDGAR
Operating Cash Flowderived$13,069,000−69.7% Free Cash Flowderived$11,131,000−73.1% Margins · derivedGross margin73.2%+2.1 pt vs Q2 2023
Operating margin-4.7%−17.7 pt vs Q2 2023
Net margin-4.8%−15.1 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 5, 2024 · 36 d after period end